Drug Profile
GS 9132
Alternative Names: ACH-806; GS-9132Latest Information Update: 05 Feb 2020
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 08 Feb 2007 Discontinued - Phase-I/II for Hepatitis C treatment in USA (unspecified route)
- 31 Jul 2006 Phase-I/II clinical trials in Hepatitis C treatment in USA (unspecified route)